Figure 2
CKD-506 decreased the infiltration of CD3 + T cells and CD68 + microglia/macrophages into the spinal cord parenchymal region in the experimental autoimmune encephalitis (EAE) mouse model on day 29 post-EAE induction. C57BL/6 mice [n = 6 per group for the fingolimod (1 mg/kg)-treated group; n = 7 per group for the non-immunized groups, CKD-506 (3, 10 mg/kg)-treated groups, and fingolimod (0.1 mg/kg)-treated group; n = 8 per group for the other groups] were orally administered CKD-506 (10, 30, or 100 mg/kg) or fingolimod (0.1 or 0.3 mg/kg) daily from day 6 post-myelin oligodendrocyte glycoprotein35–55 immunization (a–d). The number of CD3 + T cells (a), CD68 + microglia/macrophages (b), and PAX5-positive B cells (c) in the spinal cord were analyzed. (d) Representative images of immunohistochemical analysis are shown. Data are presented as mean ± SD; one-way ANOVA, followed by multiple comparisons post-hoc test with Tukey’s test for (a, b); Kruskal–Wallis test, followed by multiple comparisons post-hoc test with Dunnett’s test for (c). ###p < 0.001, non-immunized groups versus vehicle group; *p < 0.05, **p < 0.01, and ***p < 0.001, drug-treated group versus vehicle group; aaap < 0.001, CKD-506-treated group versus fingolimod (0.1 mg/kg)-treated group; bp < 0.05, bbp < 0.01, CKD-506-treated group versus fingolimod (0.3 mg/kg)-treated group; cp < 0.05, CKD-506-treated group versus fingolimod (1 mg/kg)-treated group. N, non-immunized groups; V, vehicle group; Fin, fingolimod-treated group.
